Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Barbara Burton

Clinical Genetics (M.D.) Chicago, IL Medical Doctor

NPI 1699743088 CMS profile 31005

2300 Childrens Plaza, Chicago, IL 60614

Open in the dashboard

General payments

$762,357

827 records reported · program years 2019–2025

Research payments

$12,932

Paid to them · 15 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,723,291 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Barbara Burton of Chicago, IL is reported in the CMS Open Payments database as having received $762,357 across 827 general payments and $12,932 in research payments paid to them. Separately, studies naming them as principal investigator received $5,723,291 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Clinical Genetics (M.D.) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $117,835 128
2024 General $101,533 81
2023 General $99,255 146
2023 Research $1,748 5
2022 General $105,240 91
2022 Research $1,950 3
2021 General $63,233 45
2021 Research $750 2
2020 General $84,919 69
2019 General $190,342 267
2019 Research $8,484 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Barbara Burton
  • Clinical Genetics (M.D.) median
  • Middle half of Clinical Genetics (M.D.)
  • National median

In program year 2025, general payments to Barbara Burton were reported at $117,835. Among 315 Clinical Genetics (M.D.) profiles paid that year, the median was $255 and the middle half received between $85 and $3,583.

Show as a table
Year Barbara Burton Clinical Genetics (M.D.) median Middle half National median
2019 $190,342 $130 $24–$2,691 $163
2020 $84,919 $126 $30–$3,700 $114
2021 $63,233 $185 $30–$3,777 $132
2022 $105,240 $136 $44–$2,749 $149
2023 $99,255 $196 $55–$5,220 $160
2024 $101,533 $165 $46–$3,171 $164
2025 $117,835 $255 $85–$3,583 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. BioMarin Pharmaceutical Inc. $348,038 476 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $112,698 62 payments
  3. Sanofi-Aventis U.S. LLC $40,995 13 payments
  4. Ultragenyx Pharmaceutical Inc. $37,307 17 payments
  5. Shire North American Group Inc $36,547 37 payments
  6. PTC Therapeutics, Inc. $32,692 31 payments
  7. Horizon Therapeutics plc $29,395 18 payments
  8. Genzyme Corporation $28,820 33 payments
  9. Alexion Pharmaceuticals, Inc. $22,617 32 payments
  10. Moderna TX, Inc. $18,551 65 payments
  11. Other $54,698 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $302,779 173 payments
  2. Consulting Fee $250,774 157 payments
  3. Travel and Lodging $135,860 263 payments
  4. Honoraria $35,675 17 payments
  5. Education $28,146 25 payments
  6. Food and Beverage $9,124 192 payments
Products named General payments · program years 2019–2025
  1. Palynziq $206,639 334 payments
  2. Kuvan $118,592 229 payments
  3. ELAPRASE $57,908 47 payments
  4. Vimizim $43,627 47 payments
  5. NO PRODUCT DISCUSSED $40,245 12 payments
  6. RAVICTI Ravicti $25,093 15 payments
  7. ALDURAZYME $22,016 6 payments
  8. RAVICTI Metabolic Disorders/Rare Disease $13,070 12 payments
  9. Naglazyme $12,933 12 payments
  10. DISEASE STATE $10,434 8 payments
  11. Other $37,674 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Alexion Pharmaceuticals, Inc. $4,713 4 payments
  2. BioMarin Pharmaceutical Inc. $4,071 2 payments
  3. Moderna TX, Inc. $2,400 4 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,748 5 payments

Records

842 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Genetics (M.D.) in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record